BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33237657)

  • 21. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease.
    Smardova L; Engert A; Haverkamp H; Raemakers J; Baars J; Pfistner B; Diehl V; Josting A
    Leuk Lymphoma; 2005 Jul; 46(7):1017-22. PubMed ID: 16019552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
    Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
    Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
    Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
    J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
    Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M
    Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
    Baetz T; Belch A; Couban S; Imrie K; Yau J; Myers R; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R; Crump M
    Ann Oncol; 2003 Dec; 14(12):1762-7. PubMed ID: 14630682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.
    Jeon SY; Yhim HY; Kim HS; Kim JA; Yang DH; Kwak JY
    Korean J Intern Med; 2018 Nov; 33(6):1169-1181. PubMed ID: 29295612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
    Gopal AK; Press OW; Shustov AR; Petersdorf SH; Gooley TA; Daniels JT; Garrison MA; Gjerset GF; Lonergan M; Murphy AE; Smith JC; Pagel JM
    Leuk Lymphoma; 2010 Aug; 51(8):1523-9. PubMed ID: 20578815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.
    Kosmas C; Athanasopoulos A; Dimitriadis G; Miltiadous C; Zilakos M; Lydakis D; Magiorkinis E; Gekas C; Daladimos T; Mylonakis N; Ziras N
    Anticancer Drugs; 2014 Aug; 25(7):841-7. PubMed ID: 24625457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.
    Hou Y; Wang HQ; Ba Y
    Med Oncol; 2012 Dec; 29(4):2409-16. PubMed ID: 22476761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL.
    el Aziz LM
    Med Oncol; 2014 Nov; 31(11):244. PubMed ID: 25294423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
    Liu H; Li H; Xiong W; Yi S; Zou D; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):578-82. PubMed ID: 26304082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
    Todd T; Raj S; Camilleri D; Stafford G; Bulusu R; Follows G; Williams M; Marcus R
    Ann Hematol; 2009 Nov; 88(11):1107-12. PubMed ID: 19418054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.
    Cheung MC; Hay AE; Crump M; Imrie KR; Song Y; Hassan S; Risebrough N; Sussman J; Couban S; MacDonald D; Kukreti V; Kouroukis CT; Baetz T; Szwajcer D; Desjardins P; Shepherd L; Meyer RM; Le A; Chen BE; Mittmann N;
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25868579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
    Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C
    J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience.
    Rybka J; Jurczak W; Giza A; Paszkiewicz-Kozik E; Kumiega B; Drozd-Sokołowska J; Butrym A; Kuliczkowski K; Wróbel T
    Adv Clin Exp Med; 2015; 24(5):783-9. PubMed ID: 26768628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant.
    Chiu M; Hague S; Elinder-Camburn A; Merriman E; Chan H
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):835-840. PubMed ID: 35915036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chemotherapy using gemcitabine hydrochloride for malignant lymphoma].
    Asou H; Maeda K; Takeuchi K; Kiyosawa K; Taniai H
    Gan To Kagaku Ryoho; 2013 Nov; 40(11):1489-95. PubMed ID: 24231701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
    Pavone V; Gaudio F; Guarini A; Perrone T; Zonno A; Curci P; Liso V
    Bone Marrow Transplant; 2002 Feb; 29(4):285-90. PubMed ID: 11896424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.